Brivanib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

VEGFR2 和 FGFR1 的双重抑制剂，IC50 分别为 25 nM 和 148 nM。

A dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively; shows weak activity for VEGFR1 (IC50=380 nM), and no significant activity on EGFR, PDGFRβ, Lck, etc.; demonstrates robust in vivo activity in human tumor xenograft models.Liver Cancer Phase 3 Clinical.

Brivanib inhibits VEGFR1 and FGFR-1 with IC50 of 0.38 μM and 0.148 μM. Brivanib is not sensitive to PDGFRβ, EGFR, LCK, PKCα or JAK-3 with IC50 all above 1900 nM. Brivanib could inhibit the proliferation of VEGF-stimulated HUVECs with IC50 of 40 nM, compared to 276 nM in FGF-stimulated HUVECs. On the other hand, brivanib exhibits low activity to tumor cell lines. Brivanib doses ≤20 μM paradoxically enhances FGF-induced LX-2 cell proliferation, whereas higher brivanib doses (≥30 μM) inhibits LX-2 cell proliferation. The inhibitory effect of brivanib on liver fibrosis is not through inhibition of TGF-β1-induced stellate cell activation, and is possibly through inhibition of PDGF-BB-induced stellate cell activation.

Brivanib displays antitumor activities in H3396 xenograft in athymic mice. At a dose of 60 and 90 mg/kg (p.o.), brivanib completely inhibits the tumor growth, with TGI of 85% and 97%, respectively.?Moreover, brivanib significantly suppresses tumor growth in Hepatocellular carcinoma (HCC) xenografts, which due to the decrease in phosphorylation of VEGFR2. The results show that the tumor weights in 06-0606 xenograft mice are 55% and 13%, compared with the controls at a dose of 50 mg/kg and 100 mg/kg. Brivanib is suggested to be efficient in treatment of HCC.?Brivanib (50 mg/kg, p.o.) attenuates liver fibrosis and stellate cell activation induced by BDL in mice. Brivanib inhibits growth factor and growth factor receptor mRNA expression in sham control animals but shows variable effects in bile duct ligated animals.

BMS-540215 | BMS540215 | BMS 540215

Angiogenesis

VEGFR

EGFR|FGFR1|Flk1|VEGFR1|VEGFR2

Cancer

Liver Cancer

649735-46-6

370.3776

C19H19FN4O3

>98% (HPLC)

DMSO: ≥ 50 mg/mL

FC1=C(OC2=NC=NN3C2=C(C(OC[C@H](O)C)=C3)C)C=CC4=C1C=C(C)N4

2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)-

(-20℃)

With Ice Pack

≥ 2 years